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Objective Postpartum haemorrhage (PPH) is a
significant cause of maternal morbidity and
mortality. The most common cause is an inability of
the uterus to contract adequately after childbirth. In
bimanual compression (BMC), one hand is placed
within the vagina and the other hand is on the
abdominal wall to compress the uterus. It is
effective, but very uncomfortable for the woman.
We designed a device that could replicate BMC
without inserting a hand vaginally, therefore being
less invasive. It could also help in diagnosing the
source of the bleeding.
Design Mixed methods, combining an iterative
design process with input from clinicians in
simulations, and focus groups of clinicians and
consumers.
Setting Department of Women’s and Children’s
Health and Department of Medical Physics and
Clinical Engineering, University of Liverpool, UK.
Methods A multidisciplinary team developed the
design, using an obstetric manikin. Clinician and
consumer groups also gave input on the concept
and design. A healthcare product company and
prototype manufacturer provided input into
strategy, design and manufacture.
Results The PPH Butterfly is a single piece, plastic
medical device that replicates BMC. It is designed to
be easy to use and low-cost and allows for smooth
insertion and removal. It is acceptable to clinicians
and consumers and performs well in tests.
Conclusions This is the first device designed to
replicate BMC while being less invasive. It could
potentially be an effective form of PPH
management, while also diagnosing the source of
the bleeding. The device will now be tested in
humans.
INTRODUCTION
Postpartum haemorrhage (PPH) is an
obstetric emergency that can follow
vaginal or caesarean delivery. It is esti-
mated that each year PPH accounts for
27% of the 303 000 maternal deaths
worldwide1 2 and a further 20 million
women suffer long-term effects.3
Although the absolute risk of death is
much lower in high-income countries (1
in 100 000 vs 1 in 1000 births in low-
income countries),4 and in spite of
marked improvements in management,
PPH remains a significant contributor to
maternal morbidity and mortality
throughout the world.5
A low-cost, effective intervention that
can be used by first-level maternity ser-
vices providers could be a major advance
in reducing maternal mortality from
PPH, especially in low resource settings
where the majority of deaths occur.
A vital step in the physiological preven-
tion of PPH is the immediate contraction
and retraction of myometrial muscle
fibres during and after the third stage of
labour. Uterine atony is a condition char-
acterised by the inability of the uterus to
contract adequately after the placenta has
separated from the uterus. This condition
is thought to be the most common cause
of PPH6 7 and is often unpredictable.8 Its
presentation is very similar to that of
genital trauma and often the only way to
distinguish the two is under anaesthetic
in an operating theatre. Initial treatment
therefore assumes that the cause of any
postpartum bleeding is atony, with formal
examination under anaesthetic only if
this treatment fails. However, there is evi-
dence that repeated use of uterotonics
has little effect.9–11 Furthermore,
on-going haemorrhage caused by delays
in stopping the bleeding can lead to
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coagulation problems, which only serves to worsen
the bleeding and sets up a vicious cycle. Given all this,
it is fortunate that most women with PPH stop bleed-
ing spontaneously.12 However, the inability to predict
who will stop bleeding spontaneously forces care-
givers to intervene aggressively at an early stage in the
process on all women.
THE THEORY BEHIND THE DEVICE
Bimanual compression (BMC) is an old technique in
which the uterus is compressed between a hand on
the lower abdomen and a hand inserted into the
vagina and formed into a fist. Although it is highly
effective, it is a very painful manoeuvre for the
mother (unless she has an epidural in place) and tiring
for the practitioner. The idea of the Butterfly device is
to achieve the benefits of BMC without being so inva-
sive, thus allowing it to be more widely used. It has
been designed to be a slim, easily insertable replace-
ment to a fist in the vagina, thus increasing acceptabil-
ity of uterine compression to women and clinicians.
The size and shape of the compression platform
was based on that of a shelf pessary, an intravaginal
device used for treating uterine prolapse. The depth
of insertion was based on the length of a standard
Cusco’s vaginal speculum (figure 1—shelf pessary and
Cusco’s speculum combined). This should make
uterine compression available for use at a much
earlier stage in the PPH treatment process and
provide an effective treatment without the need for
medicines or advanced diagnostic skills (figure 2).
Once inserted, the uterus is compressed against the
PPH Butterfly by a hand externally on the woman’s
abdomen. The device will be held in place by its
handle, which can be wedged against the bed, or be
held by the clinician or an assistant.
The tiring nature of traditional BMC is an import-
ant issue which limits its effectiveness. In training ses-
sions, we demonstrate this to junior doctors by asking
them to compress a book between fist and hand—but
they tire rapidly and many are unable to continue this
for more than 60 s. However, in keeping with physio-
logical principles of uterine contractions (that gener-
ally only occur every 3 min) and blood clots (that take
3–5 min to develop), a pressure period of just 1 min is
grossly inadequate except as a temporising measure.
To achieve lasting haemostasis, a compression for
8–10 min is needed and this is unlikely to be obtained
effectively with standard techniques. To enable pro-
longed pressure using the Butterfly device, the handle
is constructed so as to allow the clinician to stabilise it
against the bed once it is inserted. Thus, the clinician’s
weight can be used to stabilise the device against the
bed as well as putting pressure on the uterus—this is a
far more ergonomically efficient technique.
The PPH Butterfly is also designed to work as a
management tool that assists in the diagnosis of
primary PPH. There are four well-recognised causes
of PPH; uterine atony, genital tract trauma, retained
products of conception and bleeding disorders. The
most common causes are uterine atony followed by
genital tract trauma, but the two are often difficult to
differentiate clinically. However, if the bleeding stops
with uterine compression, the cause is almost certainly
uterine atony: if it continues then it is likely to be
from vaginal lacerations (figure 3). The surface of the
Figure 1 A composite picture combining a shelf pessary (used for the treatment of uterovaginal prolapse) and a Cusco speculum
(used for vaginal and cervical examination).
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platform of the device resembles a grill, with multiple
holes. This gives a surface against which to compress
the uterus, while preventing the trapping of blood
and clots above it.
If this concept could be realised, it could transform
care in PPH. In high resource settings, it would have
the effect of preventing anaemia, as well as the need
for anaesthetics, intensive care, blood transfusions and
the progression to clotting disorders. If it could also
be used in poorer settings where many of these tech-
nologies are unavailable, then it could also save many
mother’s lives every year.
METHODS
The PPH Butterfly was invented by Professor Weeks
and John Porter, with the intellectual property held
by the University of Liverpool. Following a grant from
NIHR i4i funding stream, prototypes were designed
and developed with the Department of Medical
Physics and Clinical Engineering, University of
Liverpool/Royal Liverpool University and Broadgreen
Hospitals NHS Trust (RLBUHT). A collaborative rela-
tionship was established with Pelican Feminine
Healthcare(Cardiff, UK) early in the project. Their
input involved an advisory role as part of a
twice-yearly Scientific Advisory Group, and optimis-
ing the computer-aided design for injection moulding
through their design team at Interplex Select Moulds
(High Wycombe, UK). The final injection moulding
of the model for in vivo testing was undertaken by
Proto Labs (Telford, UK) with assistance from
Plastribution (Ashby-de-la-Zouch, UK).
As part of the overall project, a series of focus
groups were held so as to evaluate the initial concept
Figure 2 Diagram showing the normal progression of severe PPH. Use of the PPH Butterfly should provide an early diagnosis of the
underlying cause of the bleeding while preventing on-going blood loss. PPH, postpartum haemorrhage.
Figure 3 The platform of the PPH Butterfly rests just beneath the uterine cervix (shown as a red dotted line above). Bleeding from
above the red line is usually due to uterine atony and will stop abruptly with uterine compression. That from below the red line is
from vaginal lacerations and blood loss will continue even with uterine compression. PPH, postpartum haemorrhage.
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and design and then review subsequent developments.
There were three focus groups: two comprised of
mixed groups of midwives and obstetricians, and one
comprised of local female members of the public. The
first groups explored the groups’ initial views of the
PPH Butterfly—its aesthetics, purpose, functionality
and perceived problems, and sought suggestions for
improvements. Further focus groups were held a year
later when they were updated as to the progress of the
project, saw the outcome of their previous comments
and reviewed the progression from the original
design.
Updates on the PPH Butterfly as a device, and the
project overall, were also presented 6-monthly to the
PPH Butterfly Advisory Group. This group comprised
of four individuals from the local trust (consultant
midwife, consultant obstetrician, head of risk manage-
ment and a non-executive director), a commercial
advisor (from Pelican Healthcare) and the
Commercialisation Manager from the University of
Liverpool. The group served to provide feedback and
advice on a variety of aspects of the project from an
outsider’s perspective.
RESULTS
The initial concept is loosely based on combining the
shelf pessary and Cusco’s vaginal speculum (figure 1).
The vagina immediately after delivery is however not
in its usual state as it has just been widely distended
by the passage of the fetal head. The vagina is there-
fore relatively distended and loose immediately after
childbirth, making it easier to admit a device.
To date, there have been eight major iterations of
the device with subtle adjustments made at each iter-
ation. The first model, made in the kitchen of one of
the inventors (figure 4), was made from a plastic hand
cream bottle with the side cut out with scissors and a
paediatric asthma spacer device. A wire grill was fash-
ioned to place over the cut-out section of the bottle,
and the end of the spacer was inserted obliquely into
its end. A series of coloured pin heads were inserted
into the handle to represent a pressure gauge. The
aim was to insert the device into the vagina in an
anterioposterior aligned position before rotating it
into position in the middle of the birth canal. Its
primary function was diagnostic: to separate out
blood coming from the uterus and the birth canal.
Blood from the uterus would flow through the device
and out of the end of the stalk while blood coming
from vaginal lacerations would emerge from the birth
canal around the sides of the stalk.
As discussions about the device progressed, it
became clear that the BMC function was critical to its
success. To be successful, the platform therefore
needed to be much larger, similar to that of a ‘shelf
pessary’, a gynaecological support device to support a
prolapsed uterus in women who are unfit for surgery
(figure 5). This would, however, make it much more
difficult to insert and then to hold in a stable position
during compression. The key design goals were to
achieve:
1. A platform that could allow atraumatic compression of
the uterus while allowing drainage of blood through it.
2. A system for inserting the platform into the upper
vagina without trauma or discomfort and which can be
reversed for its removal.
3. A handle to allow the user to hold the platform from
outside the birth canal and hold it stable despite up to
100N pressure on any part of the platform.
4. A safety mechanism to prevent inadvertent overinsertion
of the device.
5. A mechanism to assess how much blood is coming from
above the device and how much is coming from below
it.
6. A mechanism which allows the device to be gripped
securely against a surface under the woman’s buttocks
with minimal effort from the user.
In order to see the effects of each design change,
numerous prototypes were made. Initially, the
Figure 4 First design using hand cream bottle and asthma
spacer. Figure 5 A shelf pessary.
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prototypes from hand drawn ideas were made from
available materials or adapted from other instruments
and machines. However, as the ideas became more
developed, the Engineering department moved to
computer-aided design (CAD) with 3D printing of
APS prototypes. These served to give more of a realis-
tic feel as to how the final device would look.
Consequently, these prototype devices were used in a
series of manikin studies that were undertaken as part
of a student PhD. These studies provided information
as to clinicians’ opinion of the PPH Butterfly in com-
parison to traditional BMC. It also assessed the level
of pressure that could be achieved over a 5-min
period in a randomised trial of the two methods.
In the final device, the platform shape and size is
modelled on that of a large shelf pessary (figures 5 and
6). The addition of a handle enables the user to easily
insert the device and align it into its correct position
while the large handle limits the depth of insertion.
When folded, the device can be slipped longitudinally
into the vagina with minimal trauma. Once inserted,
the device is unfolded by sliding the two arms of the
device over each other so that the uterine platform
pivots to face anteriorly towards the maternal
abdomen (figure 7). Thus, the surface of the platform
ends up perpendicular to the axis of the uterus. On
sliding back one handle, the device will return to its
original folded state, allowing the device to be
removed without discomfort or trauma.
The PPH Butterfly is intended as a one-piece injec-
tion moulding with living hinges. It is moulded ‘open’
and folded into a stable isosceles triangle for use.
When deployed, both handles come into locked
apposition and are held locked with the grasp of the
fingers. Plan dimensions for the PPH Butterfly tri-
angle form are shown in figure 8. The platform height
was originally developed to mimic the size and shape
of a fist, although this will be in constant review
during human testing.
The device was developed in accordance with the
Medical Devices Directive standard BS EN ISO
14155:2011.
There were several areas of the device that required
particular attention and revisions.
Stability of platform (locking)
Initial designs of the device demonstrated difficulty
with the strength and stability of the platform that is
the ability of the platform to lock into place once in
use. This design feature was key to the functioning
and thus potential success of the device. There was
also concern that, unless fully stable, the platform
could suddenly dislodge/disengage and cause trauma
to the vaginal, uterus or cervix. This was a key
concern with the initial designs in which the platform
was supported by a central handle (eg, figures 9 and
11). The answer to this problem came in the triangu-
lar design (figure 8), in which the two supporting
arms are continuous with the platform and with the
handles, which can be locked together.
Platform design
The platform of the device acts as a surface against
which the uterus can be compressed. It was estimated
that it needed to be strong enough to support 10 kg
of pressure. However, it also needed to have large per-
forations so as to allow blood and small clots to flow
through it. If clots could not pass through the plat-
form, then they could build up above it and give the
impression that bleeding had stopped when in fact it
was simply being held back inside the uterus.
Initial designs had a central drainage channel that
brought blood and clots through the platform and
along the central handle (figure 9). There was concern
however that a single channel could easily be blocked
off by loose cervical tissue and so the decision was
made to make numerous large perforations in a plat-
form, large enough to allow small blood clots to pass
but leaving enough residual material to support the
compression.
Consideration then turned to the platform design,
attempting to produce a design that had holes large
enough for small blood clots to pass through, but
Figure 6 The final design of the platform.
Figure 7 The PPH Butterfly being inserted into the manikin (previous design of the device). PPH, postpartum haemorrhage.
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small enough to restrict the passage of the uterus or
cervix itself. Any barrier also had to be atraumatic to
the lower part of the uterus (ie, without a ‘cheese
wire’ cutting effect) and not allow the passage of soft
tissue through the perforations which could then swell
and be trapped distal to the uterus. Ideally, it would
also be aesthetically appealing. Several designs were
put to the focus groups, including some where the
perforations formed recurring patterns or pictures. An
abstract design with variable sized perforations with a
depth of at least 4 mm was finally settled on which
remains in use in the first in vivo device (figure 6).
The size of the platform was not easy to determine
but was based on the dimensions of a flat hand and
clenched fist as used in BMC. The birth canal immedi-
ately after childbirth has just been widely distended
with the passage of a baby’s head. This is typically
10 cm diameter at the time of birth, and the resulting
distension of the birth canal is thought to remain for
several hours after birth. It is this distension that gives
space for the insertion of a clinician’s flat hand into
the vagina and space to clench it into a fist for BMC.
These dimensions were therefore chosen for the initial
in vivo version of the device.
Subsequent testing of the device in five normal post-
natal women revealed that the platform design was
too large. For subsequent human tests, two sizes were
therefore produced with reduced dimensions of
8.0×5.9 cm and 6.9×5.0 cm.
Living hinges
To facilitate folding of the arms, the device has ‘living
hinges’ at either side of the platform. This is a section
of the device between the platform and the arms
where the plastic suddenly narrows to 2 mm thickness,
thus producing a natural point at which the device will
crease. This allows the device to be moulded in a
single part, reducing its complexity and price.
Although a living hinge is strong, there is the potential
for tearing after repeated folding. Initially, however,
these hinges are strong and carry no risk of tearing
during the single use that the device is made for.
The first injection-moulded prototype had a living
hinge that extended right along both sides of the plat-
form. Once folded, this formed a sharp ridge along
the leading edge of the platform, which would be
likely to cause trauma to the vaginal walls during
insertion (figure 12). The platform edge was therefore
redesigned to recess the living hinge behind two
lateral pedicles (figure 13). This gave a smooth
leading edge, but also gave the advantage of added
stability once in the compression position. In the first
injection mould, the total compression force was
borne by the living hinges. In the redesign, however,
the pedicles took the full force of the compression as
soon as there was any give in the hinges. This gave
greater stability and weight bearing ability.
Figure 8 Design diagram showing original dimensions of the PPH Butterfly once folded for use. PPH, postpartum haemorrhage.
Figure 9 The original design from which the name PPH
Butterfly originated. The two wings on either side of the
platform fold together for insertion, opening up once within the
vagina. Channels on the surface of the wings direct blood
down into the drainage channel that runs through the centre of
the handle. PPH, postpartum haemorrhage.
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Minimising trauma
In order to aid the ease of insertion and minimise any
potential trauma to women, the device edges have
been rounded as much as possible. A plastic was also
selected for manufacture that had a smooth surface
and could be lubricated with one of the water-soluble
gels commonly used in hospitals. In the injection-
moulded prototypes, flashes and joint ridges were
smoothed out by hand prior to sterilisation and clin-
ical use. The change in hinge design (see above) also
minimised trauma.
Preventing overinsertion
During formal risk assessment, it was identified that
there was a danger of inexperienced users inserting
the device too far into the birth canal and so dam-
aging the top of the vagina. It was therefore planned
that a guard or shield would be added halfway up the
handle of the PPH Butterfly to act as a safety mechan-
ism by indicating to clinicians how far the device
could be inserted safely. Its distance from the platform
was based on the length of an adult Cusco’s speculum,
an instrument for inspection of the cervix which is in
common hospital use. It was subsequently decided
that a guard could cause confusion and that it would
be better to simply increase the size of the handle of
the device. This not only clearly indicates the limit of
insertion, but it also prevents overinsertion through its
large size (figures 7 and 9).
Handle—inclusion of finger holes
The Butterfly handle varied in material, shape and
length over the course of the design process.
Concerns were raised as to the difficulty and discom-
fort that would be experienced when having to grip
the handles for the length of time that would be
necessary to compress the uterus effectively. The solu-
tion came with the inclusion of five finger holes in a
wide handle for the user’s fingers to go through
(figure 14). Placing the user’s fingers through the
holes not only held the two sides firmly together even
in the presence of blood or other body fluids, but also
gave a stable grasp for the user. The inclusion of the
finger holes allows for variation in the way that the
device can be held by the user: the device can either
Figure 10 A variety of platform designs (in chronological order from left to right) showing the evolution of the design.
Figure 11 This iteration has a compression gauge as part of
the central pillar supporting the platform (note the draft pulley
system, designed to pivot the platform from a longitudinal
position for insertion into a horizontal position for use).
Figure 12 The initial hinge design—strong but with a sharp
leading edge that could result in trauma on insertion.
Figure 13 The redesigned shorter hinge. The sharp edges of
the folded living hinge are now recessed behind extensions to
the platform. Once folded for use, each arm has two pedicles
lateral to the hinge that rest over the outer edges of the
platform. As soon as the hinge starts to ‘give’ with pressure,
these pedicles push tight against the platform thus ensuring
strength and stability.
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be held ‘in-line’ with the Butterfly stem in continuity
with the forearm when in use or the hand can hold
the handle from above. This allows the user to push
the handle into the bed beneath the woman to hold it
stable. This should provide a less tiring position for
the user as his/her body weight can be used to simul-
taneously compress the uterus and hold the device in
place.
Material choice
A material had to be chosen that is suitable for
internal use in women, while being robust, smooth
and economical. Polypropylene was an obvious choice
for this. The TOTAL product PPM H250 was chosen
as it is ‘a narrow molecular weight distribution homo-
polymer with a Melt Flow Index of 25 g/10 min,
recommended for the manufacture of medical pack-
aging and medical devices, to the exclusion of
implants’ (TOTAL, 2013).
Naming the device
The ‘PPH Butterfly’ name was initially chosen
because the earlier incarnations of the device had
operated in such a way that when opened, the plat-
form of the device resembled a pair of wings, like that
of a butterfly. When the design changed to a platform
with folding arms, it was felt this resemblance was
lost, and a change in name to ‘PPH Shelf ’ (after the
shelf pessary on which the device is based) was con-
sidered. However, this option was not at all popular
with the focus groups, and it was decided to retain
the original name of ‘PPH Butterfly’.
Blood collection
The original concept of the device was that it would
divide the genital tract into two and separate any
blood coming from above the device from that
coming from below. This can be seen in the very first
home-made prototype (figure 4) where blood from
above the device passed through the grill and down
the handle. This was later modified so that the plat-
form had channels along which blood flowed into a
central stalk (figure 9). The realisation that a central
hinge in the platform would be a point of weakness
led to the production of a solid platform (figure 10).
This would need to be twisted to allow its
Figure 14 (A–D) The final iteration of the device. The device is folded flat for insertion (A) and then the handles brought together
so as to create a stable triangular structure to support the weigh-bearing platform (B). The handles are held together by
complimentary protrusion and recesses in the handle as well as by the finger grips. The device can be held in a longitudinal fashion
(C) to mimick standard bimanual compression. For women lying on a bed, the handle can be stabilised from above (D) so as to
wedge the handle onto the bed. This mechanism should be less tiring for the clinician as he/she can use their body weight to put
pressure on the uterus as well as to hold the device in position.
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longitudinal insertion into the birth canal, complicat-
ing the drainage of blood. A suggestion came from a
focus group to attach a blood collection bag to the
rear of the platform. The aim of the bag was to
collect any blood coming through the platform and
give a physical recording of the amount of blood that
had been lost while the device was in use. It would
also have enabled a visual assessment and quantifica-
tion of the volume and source of the blood loss.
While an attractive option, the bag would have added
complexity to the manufacture, and there were fears
that it would be compressed in the birth canal and
prevent blood entering it. Furthermore, an assessment
of the source of the bleeding could be made without
the bag: if the bleeding stopped as the uterus was
compressed, then you would know the bleeding was
uterine in origin. If it continued during uterine com-
pression, then you would know that it was from
vaginal lacerations. Consequently, it was agreed that
the bag provided considerable complexity for little
added benefit and it was removed.
Compression gauge
Earlier in the design process consideration was given
to the inclusion of a compression gauge that would
provide feedback as to the level of pressure that was
being used to compress the uterus. This can be seen in
figure 11.
This was to be sited along the handle and would
have provided biofeedback to the user as to whether
the pressure was adequate. However, when measure-
ments were taken of the pressure exerted by 10
experts on the uterus of a manikin during BMC, the
pressures were found to be highly variable. It was not
therefore possible to provide a standard pressure, and
the compression gauge was abandoned.
Device assessment and risk management
During initial BMC measurements in a manikin with
prototype PPH Butterfly devices, peak levels of 42 N
were recorded.
Subsequent stress testing of real prototypes (PPH
Model (2) A, B and C), as part of the Medicines and
Healthcare Products Regulatory Agency (MHRA) sub-
mission, demonstrated devices could withstand forces
of up to 902, 1140 and 1122N, respectively, without
buckling.
Feedback was obtained throughout the design
period from clinicians who compared the PPH
Butterfly device and BMC in an obstetric manikin. In
initial studies, a commercial potato masher was used
as a substitute for the device but this was replaced by
3D printed prototypes once available. A final cross-
over study compared the uterine pressures generated
by the device and bimanually in 20 doctors who had
previous experience of undertaking BMC and 22 mid-
wives who had no experience of it. The study mea-
sured maximum pressure generated as well as total
pressure over a period of 5 min. There was no differ-
ence in the mean or maximum uterine pressures gen-
erated using BMC or the PPH Butterfly and no
difference between the two groups.
DISCUSSION
Now that the design of the PPH Butterfly is complete,
the next step in the project is to test the device in
postnatal humans—normal and in those with bleed-
ing. Initial tests on normal postnatal bleeding will
assess the size of the platform and handles as well as
the mechanism for insertion. Once this has been
explored, it will then be necessary to determine that
the PPH Butterfly can effectively manage PPH.
If successful, the PPH Butterfly has the potential to
make a significant impact on PPH management. This
would be particularly true within the developing
world, where there is limited access to resources. The
PPH Butterfly has been designed specifically with
these countries in mind, with particular attention
being paid to the overall cost of the device, which has
been kept as low as possible, while not compromising
the design. While it is designed to be single use and
disposable in the UK, there are also plans to make a
version that can be sterilised and re-used for low
resource settings. This will allow it to reach a much
wider number of women than would be possible if it
only withstood one use.
The use of BMC to treat PPH is limited by its inva-
sive nature and how tiring it is for the clinician. These
factors currently limit its use to those who are bleed-
ing very heavily where its efficacy is likely to be the
lowest. Consequently, its effectiveness is not demon-
strated, which in turn leads to a further reluctance
from clinical staff to use it as a method of PPH
management.
Suggestions have been made by the design team and
members of the focus groups for ways in which the
device could be enhanced, such as the inclusion of a
light on the handle, and the addition of a soft cover-
ing or local haemostatics to the platform. While such
additions may enhance the device, they are not neces-
sary in relation to the basic function of the PPH
Butterfly and instead could be seen as potential future
‘add-ons’.
Discussions with focus groups during the course of
the project have provided the project team with real
time feedback as to the design of the device and pos-
sible ideas for its development. Currently, the device
needs to achieve basic functionality, while being safe
and cost-effective. Once these aspects have been
proven, it may be possible in the future for there to be
some ‘add-ons’ to the device, at an additional cost.
The focus groups facilitated the opportunity to view
the device from a different perspective. Having focus
groups comprised of clinicians and members of the
public allowed the project team to see past their own
enthusiastic viewpoint and also gave an appreciation
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of the way in which the PPH Butterfly may be seen by
those women it could be used on. This was useful
prior to beginning any recruitment to the human
studies of the project, as it allowed the project team to
carefully consider the best way in which to identify
and approach women, as well as how to project the
PPH Butterfly and the study itself, in order to increase
the likelihood of participation.
CONCLUSIONS
The PPH Butterfly is a novel device designed to treat
PPH through uterine compression. It is built to be less
invasive and less tiring than traditional BMC. Clinical
assessments are currently being undertaken to deter-
mine its safety and effectiveness in PPH management.
Correction notice This article has been corrected since it was
published Online First. Figures 9-13 were published in the
wrong order. This has now been amended.
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